Abstract 592P
Background
Debate surrounds the surgical management of Goblet cell adenocarcinoma (GCA). However, right hemicolectomy (RHC) remains the standard surgical choice for GCA.
Methods
1154 and 867 patients with GCA were extracted from U.S. Surveillance, Epidemiology, and End Results (SEER) and National Cancer Registration and Analysis Service (NCRAS) databases respectively after excluding patients with missing data. Two clusters for each cohort were created using an unsupervised machine learning K-means model (cluster 0, cluster 1). Clustering was evaluated using silhouette (S), Davies Boulden (DB) and Caliniski Harabasz (CH) scores. Clusters were visualised using principal component analysis (PCA) and T-distributed stochastic neighbour embedding (T-SNE). SHapley Additive exPlanations (SHAP) identified clinical features that were the most useful in clustering. Kaplan Meier (KM) statistics and graphs were generated. Decision trees were developed to cluster individual patients in each of the two clusters.
Results
PCA and T-SNE visualisations showed distinct clusters with some overlap in both cohorts. SHAP revealed tumour size and stage as important variables for clustering in SEER, while age and stage were key variables in NCRAS. Clusters description and survival are shown in the table. The two clusters were statistically different in survival based on Cox regression, Log-rank test and KM statistics in both cohorts. Appendectomy and RHC showed similar survival rates across both cohorts and within each cluster of both cohorts. Table: 592P
Characteristics of clusters and 5-year survival rates
Characteristic | Clustrer 0Favourable survival | Cluster 1Unfavourable survival |
Median age, years (SEER) | 58 | 59 |
Male sex, % (SEER) | 48 | 54 |
Localised stage, % (SEER) | 64 | 33 |
Distant stage, % (SEER) | 3 | 19 |
Tumour size, median mm (SEER) | 14 | 50 |
5-year survival, % (95% CI) (SEER) | 85(82-88) | 72(59-72) |
Median age, years (NCRAS) | 48 | 68 |
Male sex, % (NCRAS) | 56 | 43 |
Localised stage, % (NCRAS) | 90 | 81 |
Distant stage, % (NCRAS) | 4 | 9 |
5-year survival, % (95% CI) (NCRAS) | 87(83-91) | 61(57-66) |
Conclusions
After categorising cases into two clusters using unsupervised machine learning, RHC and appendectomy demonstrated comparable survival rates among patients with GCA. Machine learning could facilitate clinicians in exploring the impact of various treatment approaches on survival outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Hampshire Hospitals NHS Foundation Trust.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
566P - Impact of weekly irinotecan’s cycles during preoperative chemoradiotherpy in locally advanced rectal cancer: A post-hoc analysis of the CinClare study
Presenter: Ji Zhu
Session: Poster session 16
567P - Interim endoscopic restaging after induction chemotherapy to predict complete response and survival after total neoadjuvant therapy in low rectal cancer: Ad-hoc analysis of the IMPACT trial
Presenter: Eiji Shinozaki
Session: Poster session 16
568P - Risk factors for recurrence after surgery for rectal cancer in a modern, nationwide population-based cohort
Presenter: Sepehr Doroudian
Session: Poster session 16
569P - Mismatch repair deficient, stage II/III rectal cancer: Real-world patient, tumour, and treatment characteristics in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
571P - Neoadjuvant chemotherapy with FOLFIRINOX and short course radiotherapy in locally advanced rectal caner (ISANOX): A prospective phase II trial
Presenter: Feryel Letaief-Ksontini
Session: Poster session 16
572P - Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34 – FFCD 1402 - ADAGE randomized phase III trial
Presenter: Thomas Aparicio
Session: Poster session 16
573P - M9140, an anti-CEACAM5 antibody drug conjugate (ADC), in patients with metastatic colorectal cancer (mCRC): Updated results from a phase I trial
Presenter: Valentina Boni
Session: Poster session 16
574P - First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 + bevacizumab (beva) in patients (pts) with advanced colorectal cancer (CRC): A phase I study
Presenter: Zhen Yu Lin
Session: Poster session 16
575P - Phase Ib/II study of ompenaclid (RGX-202-01), a first-in-class oral inhibitor of the creatine transporter SLC6A8, in combination with FOLFIRI and bevacizumab (BEV) in RAS mutated (RASmt) second-line (2L) advanced/metastatic colorectal cancer (mCRC): Updated results
Presenter: Andrew Hendifar
Session: Poster session 16